Condition: Oral Squamous Cell Carcinoma · Neoadjvant Therapy · Anti-PD-1 · Sponsor: Shanghai Jiao Tong University School of Medicine
To evaluate the efficacy of neoadjuvant anti-PD-1 plus anti-VEGFR therapy for patients with locally advanced and resectable oral squamous cell carcinoma, and the CPS\>10 in the biopsy samples.
This description comes directly from the study's public registry record.
Lai-ping Zhong, MD, PhD · +862123271699 · zhonglp@hotmail.com
Always discuss trial participation with your own doctor first.
| Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05069857